Loading...
New

Hydroxychloroquine Market by Product type (Tablet and Active Pharmaceutical Ingredients), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Specialty Drug Store, and Retail Pharmacy), and Disease (Malaria, Rheumatoid Arthritis, Lupus Erythematosus, Coronavirus, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027

A07137
Pages: 246
Sep 2020 | 822 Views
 
Author(s) : Yamini Parihar , Eswara Prasad
Tables: 120
Charts: 73
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Hydroxychloroquine Market

Request Now !

Hydroxychloroquine Market Outlook - 2027

The global hydroxychloroquine market size was valued at $1.9 billion in 2019, and is anticipated to generate $4.6 billion by 2027. The market is projected to experience growth at a CAGR of 7.9% from 2020 to 2027.  

Hydroxychloroquine is being used in treatment of COVID-19 patients since the initial stage during the wake of the pandemic. The demand for the drug has multiplied ten folds, however, the drug has been in the controversy for its efficacy in the treatment.

Hydroxychloroquine is an anti-malarial drug, which is primarily used to treat acute attacks of malaria. In addition, it is widely used as disease-modifying anti-rheumatic drug (DMARD).

Hydroxychloroquine-Market,-2020-2027

Get more information on this report : Request Sample Pages

 

India is one of the largest producers of hydroxychloroquine. The potential of this drug in treating COVID-19 enforced India to impose a ban on the export of the drug, which led to tension in U.S.–India diplomatic relations. At present, around 80 nations across the globe are dependent on the medication on India.

The key players operating in the hydroxychloroquine industry are Cadila Healthcare Ltd., Hikma Pharmaceuticals PLC, Ipca Laboratories Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Taj Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Zydus Cadila. The players are continuously focusing on R&D toward finding the impact of several coatings on coronavirus.

Hydroxychloroquine Market
By Product Type

Your browser does not support the canvas element.

Tablets is projected as the most lucrative segment.

Get more information on this report : Request Sample Pages

Hydroxychloroquine Market, by Product type  

Depending on product type, the market is bifurcated in tablet and active pharmaceutical ingredients. The active pharmaceutical ingredients segment dominated the market in 2019. However, tablet segment is attributed to the easy availability of the product in tablet form thus, is expected to grow at higher CAGR. In addition, surge in high demand for tablet, owing to its cost-effectiveness and ease of consumption drives the hydroxychloroquine market growth.

Hydroxychloroquine Market
By Distribution Channel

Your browser does not support the canvas element.

Online Pharmacy is projected as the most lucrative segment.

Get more information on this report : Request Sample Pages

Hydroxychloroquine Market, by Distribution Channel 

On the basis of distribution channel, the market is divided into hospital pharmacy, online pharmacy, specialty drug store, and retail pharmacy. The online pharmacy segment is projected to witness a considerable growth rate during the forecast period, due to continuous expansion the e-commerce sector. Increase in penetration of e-commerce sector in the pharmaceutical industry during the outbreak, lack of availability of the medicine in hospital pharmacy & retail pharmacy, time-saving feature, and the facility of home delivery provided by online platforms during the lockdown contribute toward the market growth.

Hydroxychloroquine Market
By Application

Your browser does not support the canvas element.

Malaria is projected as the most lucrative segment.

Get more information on this report : Request Sample Pages

Hydroxychloroquine Market, by Disease

By disease, the malaria segment is projected to hold largest hydroxychloroquine market share in 2019. This is attributed to alarming increase in prevalence of malaria and widespread use of hydroxychloroquine as an anti-malarial drug. Moreover, there are still countries in African region considered as malaria endemic, that still drives the demand for the drug. In-addition, HCQ is also listed under essential medicine by World Health organization.

Hydroxychloroquine Market
By Region

2027
Asia-pacific 
Europe
Lamea

Asia-Pacific is projected as the most lucrative market.

Get more information on this report : Request Sample Pages

Hydroxychloroquine Market, by Region

Region wise, Asia-Pacific held the largest market share in 2019. The dominance of the Asia-Pacific region is attributed to the presence of major market players like India and China in this region and surge in demand for the medication due to high incidence rate of malaria in South-east Asian countries.

Key Benefits For Stakeholders

  • The report provides an in-depth analysis and hydroxychloroquine market forecast along with the current trends and future estimations.
  • This report highlights the key drivers, opportunities, and restraints of the hydroxychloroquine market along with the impact analysis during the forecast period.
  • Porter’s five forces analysis helps to analyze the potential of the buyers & suppliers and the competitive scenario of the hydroxychloroquine industry for strategy building.
  • A comprehensive analysis of the factors that drive and restrain the hydroxychloroquine market growth is provided.
  • The qualitative data about the hydroxychloroquine market trends, dynamics, and developments is provided in the report.
  • The hydroxychloroquine market size is provided in terms of revenue.
  • The report provides extensive qualitative insights on the segments and regions exhibiting favorable market share.

Key Market Segments

By Product type  

  • Tablet
  • Active pharmaceutical ingredients

By Distribution Channel 

  • Hospital Pharmacy
  • Online Pharmacy
  • Specialty Drug Store
  • Retail Pharmacy 

By Disease

  • Malaria
  • Rheumatoid Arthritis
  • Lupus Erythematosus
  • Coronavirus
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific 
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific 
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA 

Key Players

  • Cadila Healthcare Ltd
  • Hikma Pharmaceuticals PLC
  • Ipca Laboratories Ltd
  • Mylan N.V
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Taj Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd
  • Zydus Cadila
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Primary research
1.4.2.Secondary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top Player Positioning
3.2.3.Porter's five forces analysis

3.3.Patent Analysis
3.4.Value chain analysis
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in demand for HCQ as potential treatment source amidst pandemic
3.5.1.2.Increase in cases of malaria

3.5.2.Restraint

3.5.2.1.Several side-effects of the medicine
3.5.2.2.Ban from several countries owing to lacking study data
3.5.2.3.Ongoing research and positive results of other drugs for potential cure

3.5.3.Opportunity

3.5.3.1.Repurposing hydroxychloroquine as anti-cancer drug

3.6.Impact of CORONA (COVID 19) outbreak on global hydroxychloroquine market

CHAPTER 4:HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Tablet

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region

4.3.Active pharmaceutical ingredient

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region

CHAPTER 5:HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospital pharmacy

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region

5.3.Retail pharmacy

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region

5.4.Online pharmacy

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region

5.5.Specialty drug store

5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by region

CHAPTER 6:HYDROXYCHLOROQUINE MARKET, BY DISEASES

6.1.Overview

6.1.1.Market size and forecast

6.2.Malaria

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region

6.3.Rheumatoid arthritis

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region

6.4.Lupus Erythematosus

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region

6.5.Coronavirus

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by region

6.6.Others

6.6.1.Key market trends, growth factors, and opportunities
6.6.2.Market size and forecast, by region

CHAPTER 7:HYDROXYCHLOROQUINE MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by product type
7.2.3.Market size and forecast, by distribution channel
7.2.4.Market size and forecast, by disease
7.2.5.Market share analysis, by country
7.2.6.U.S.

7.2.6.1.Market size and forecast, by product type
7.2.6.2.Market size and forecast, by distribution channel
7.2.6.3.Market size and forecast, by disease

7.2.7.Canada

7.2.7.1.Market size and forecast, by product type
7.2.7.2.Market size and forecast, by distribution channel
7.2.7.3.Market size and forecast, by disease

7.2.8.Mexico

7.2.8.1.Market size and forecast, by product type
7.2.8.2.Market size and forecast, by distribution channel
7.2.8.3.Market size and forecast, by disease

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by product type
7.3.3.Market size and forecast, by distribution channel
7.3.4.Market size and forecast, by disease
7.3.5.Market share analysis, by country
7.3.6.Germany

7.3.6.1.Market size and forecast, by product type
7.3.6.2.Market size and forecast, by distribution channel
7.3.6.3.Market size and forecast, by disease

7.3.7.France

7.3.7.1.Market size and forecast, by product type
7.3.7.2.Market size and forecast, by distribution channel
7.3.7.3.Market size and forecast, by disease

7.3.8.UK

7.3.8.1.Market size and forecast, by product type
7.3.8.2.Market size and forecast, by distribution channel
7.3.8.3.Market size and forecast, by disease

7.3.9.Italy

7.3.9.1.Market size and forecast, by product type
7.3.9.2.Market size and forecast, by distribution channel
7.3.9.3.Market size and forecast, by disease

7.3.10.Spain

7.3.10.1.Market size and forecast, by product type
7.3.10.2.Market size and forecast, by distribution channel
7.3.10.3.Market size and forecast, by disease

7.3.11.Rest of Europe

7.3.11.1.Market size and forecast, by product type
7.3.11.2.Market size and forecast, by distribution channel
7.3.11.3.Market size and forecast, by disease

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by product type
7.4.3.Market size and forecast, by distribution channel
7.4.4.Market size and forecast, by disease
7.4.5.Market share analysis, by country
7.4.6.China

7.4.6.1.Market size and forecast, by product type
7.4.6.2.Market size and forecast, by distribution channel
7.4.6.3.Market size and forecast, by disease

7.4.7.Japan

7.4.7.1.Market size and forecast, by product type
7.4.7.2.Market size and forecast, by distribution channel
7.4.7.3.Market size and forecast, by disease

7.4.8.India

7.4.8.1.Market size and forecast, by product type
7.4.8.2.Market size and forecast, by distribution channel
7.4.8.3.Market size and forecast, by disease

7.4.9.Australia

7.4.9.1.Market size and forecast, by product type
7.4.9.2.Market size and forecast, by distribution channel
7.4.9.3.Market size and forecast, by disease

7.4.10.South Korea

7.4.10.1.Market size and forecast, by product type
7.4.10.2.Market size and forecast, by distribution channel
7.4.10.3.Market size and forecast, by disease

7.4.11.Rest of Asia-Pacific

7.4.11.1.Market size and forecast, by product type
7.4.11.2.Market size and forecast, by distribution channel
7.4.11.3.Market size and forecast, by disease

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by product type
7.5.3.Market size and forecast, by distribution channel
7.5.4.Market size and forecast, by disease
7.5.5.Market share analysis, by country
7.5.6.Brazil

7.5.6.1.Market size and forecast, by product type
7.5.6.2.Market size and forecast, by distribution channel
7.5.6.3.Market size and forecast, by disease

7.5.7.Saudi Arabia

7.5.7.1.Market size and forecast, by product type
7.5.7.2.Market size and forecast, by distribution channel
7.5.7.3.Market size and forecast, by disease

7.5.8.South Africa

7.5.8.1.Market size and forecast, by product type
7.5.8.2.Market size and forecast, by distribution channel
7.5.8.3.Market size and forecast, by disease

7.5.9.Rest of LAMEA

7.5.9.1.Market size and forecast, by product type
7.5.9.2.Market size and forecast, by distribution channel
7.5.9.3.Market size and forecast, by disease

CHAPTER 8:COMPANY PROFILES:

8.1.Cadila Healthcare Limited

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Product portfolio
8.1.4.Business performance

8.2.Hikma Pharmaceuticals PLC

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Product portfolio
8.2.4.Business performance

8.3.IPCA Laboratories Ltd.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Product portfolio
8.3.4.Business performance
8.3.5.Key Developmental strategies

8.4.Mylan N.V.

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Product portfolio
8.4.4.Business performance
8.4.5.Key Developmental strategies

8.5.Novartis International AG

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.Pfizer Inc.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Product portfolio
8.6.4.Business performance

8.7.Sanofi S.A.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Product portfolio
8.7.4.Business performance

8.8.Taj Pharma Group

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Product portfolio

8.9.Teva Pharmaceutical Industries Ltd.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Product portfolio
8.9.4.Business performance

8.10.Torrent Pharmaceuticals Limited

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
8.10.4.Business performance

LIST OF TABLES

TABLE 01.GLOBAL HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 02.HYDROXYCHLOROQUINE MARKET FOR TABLET, BY REGION, 2019–2027 ($MILLION)
TABLE 03.HYDROXYCHLOROQUINE MARKET FOR ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 2019–2027 ($MILLION)
TABLE 04.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 05.HYDROXYCHLOROQUINE MARKET FOR HOSPITAL PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 06.HYDROXYCHLOROQUINE MARKET FOR RETAIL PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 07.HYDROXYCHLOROQUINE MARKET FOR ONLINE PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 08.HYDROXYCHLOROQUINE MARKET FOR SPECIALTY DRUG STORE, BY REGION, 2019–2027 ($MILLION)
TABLE 09.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISEASES, 2019–2027 ($MILLION)
TABLE 10.HYDROXYCHLOROQUINE MARKET FOR MALARIA, BY REGION, 2019–2027 ($MILLION)
TABLE 11.HYDROXYCHLOROQUINE MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2019–2027 ($MILLION)
TABLE 12.HYDROXYCHLOROQUINE MARKET FOR LUPUS ERYTHEMATOSUS, BY REGION, 2019–2027 ($MILLION)
TABLE 13.HYDROXYCHLOROQUINE MARKET FOR CORONAVIRUS, BY REGION, 2019–2027 ($MILLION)
TABLE 14.HYDROXYCHLOROQUINE MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 15.HYDROXYCHLOROQUINE MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 16.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 17.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 18.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 19.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 20.U.S. HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 21.U.S. HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 22.U.S. HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 23.CANADA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 24.CANADA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 25.CANADA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 26.MEXICO HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 27.MEXICO HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 28.MEXICO HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 29.EUROPE HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 30.EUROPE HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 31.EUROPE HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 32.EUROPE HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 33.GERMANY HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 34.GERMANY HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 35.GERMANY HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 36.FRANCE HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 37.FRANCE HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 38.FRANCE HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 39.UK HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 40.UK HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 41.UK HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 42.ITALY HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 43.ITALY HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 44.ITALY HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 45.SPAIN HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 46.SPAIN HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 47.SPAIN HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 48.REST OF EUROPE HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 49.REST OF EUROPE HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 50.REST OF EUROPE HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 51.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 52.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 53.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 54.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 55.CHINA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 56.CHINA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 57.CHINA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 58.JAPAN HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 59.JAPAN HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 60.JAPAN HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 61.INDIA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 62.INDIA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 63.INDIA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 64.AUSTRALIA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 65.AUSTRALIA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 66.AUSTRALIA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 67.SOUTH KOREA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 68.SOUTH KOREA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 69.SOUTH KOREA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 70.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 73.LAMEA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 74.LAMEA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 75.LAMEA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 76.LAMEA HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 77.BRAZIL HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 78.BRAZIL HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 79.BRAZIL HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 80.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 81.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 82.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 83.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 84.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 85.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 86.REST OF LAMEA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 87.REST OF LAMEA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 88.REST OF LAMEA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 89.ZYDUS CADILA: COMPANY SNAPSHOT
TABLE 90.ZYDUS CADILA: PRODUCT PORTFOLIO
TABLE 91.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 92.HIKMA: COMPANY SNAPSHOT
TABLE 93.HIKMA: PRODUCT PORTFOLIO
TABLE 94.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 95.IPCA: COMPANY SNAPSHOT
TABLE 96.IPCA: PRODUCT PORTFOLIO
TABLE 97.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 98.IPCA: PRODUCT PORTFOLIO
TABLE 99.MYLAN: COMPANY SNAPSHOT
TABLE 100.MYLAN: PRODUCT PORTFOLIO
TABLE 101.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 102.MYLAN: PRODUCT PORTFOLIO
TABLE 103.NOVARTIS: COMPANY SNAPSHOT
TABLE 104.NOVARTIS: OPERATING SEGMENTS
TABLE 105.NOVARTIS: PRODUCT PORTFOLIO
TABLE 106.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 107.PFIZER INC.: COMPANY SNAPSHOT
TABLE 108.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 109.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 110.SANOFI: COMPANY SNAPSHOT
TABLE 111.SANOFI: PRODUCT PORTFOLIO
TABLE 112.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 113.TAJ: COMPANY SNAPSHOT
TABLE 114.TAJ: PRODUCT PORTFOLIO
TABLE 115.TEVA: COMPANY SNAPSHOT
TABLE 116.TEVA: PRODUCT PORTFOLIO
TABLE 117.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 118.TORRENT: COMPANY SNAPSHOT
TABLE 119.TORRENT: PRODUCT PORTFOLIO
TABLE 120.OVERALL FINANCIAL STATUS ($MILLION)

LIST OF FIGURES

FIGURE 01.KEY MARKET SEGMENTS
FIGURE 02.EXECUTIVE SUMMARY, BY SEGMENT
FIGURE 03.EXECUTIVE SUMMARY, BY COUNTRY
FIGURE 04.TOP INVESTMENT POCKETS
FIGURE 05.TOP PLAYER POSITIONING
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.HIGH THREAT OF NEW ENTRANTS
FIGURE 08.LOW THREAT OF SUBSTITUTES
FIGURE 09.HIGH INTENSITY OF RIVALRY
FIGURE 10.HIGH BARGAINING POWER OF BUYERS
FIGURE 11.PATENT ANALYSIS FOR HYDROXYCHLOROQUINE
FIGURE 12.VALUE CHAIN ANALYSIS FOR HYDROXYCHLOROQUINE MARKET
FIGURE 13.HYDROXYCHLOROQUINE MARKET DYNAMICS
FIGURE 14.GLOBAL HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILILION)
FIGURE 15.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR TABLET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR ACTIVE PHARMACEUTICAL INGREDIENT, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 17.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILILION)
FIGURE 18.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR SPECIALTY DRUG STORE, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 22.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISEASES, 2019–2027 ($MILILION)
FIGURE 23.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR MALARIA, BY COUNTRY,  2019 & 2027 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR LUPUS ERYTHEMATOSUS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR CORONAVIRUS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 27.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 28.U.S. HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 29.CANADA HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 30.MEXICO HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 31.GERMANY HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 32.FRANCE HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 33.UK HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 34.ITALY HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 35.SPAIN HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 36.REST OF EUROPE HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 37.CHINA HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 38.JAPAN HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 39.INDIA HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 40.AUSTRALIA HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 41.SOUTH KOREA HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 42.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 43.BRAZIL HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 44.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 45.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 46.REST OF LAMEA HYDROXYCHLOROQUINE MARKET REVENUE, 2019–2027 ($MILLION)
FIGURE 47.ZYDUS CADILA: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.ZYDUS CADILA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 49.ZYDUS CADILA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 50.HIKMA: NET SALES, 2017–2019 ($MILLION)
FIGURE 51.HIKMA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 52.HIKMA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 53.IPCA: NET SALES, 2017–2019 ($MILLION)
FIGURE 54.IPCA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 55.IPCA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 56.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 57.MYLAN: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 58.MYLAN: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 59.MYLAN: REVENUE SHARE BY COUNTRY OF SUNSIDIARIES, 2019 (%)
FIGURE 60.KOBE: NET SALES, 2017–2019 ($MILLION)
FIGURE 61.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 62.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 63.NOVARTIS: REVENUE SHARE BY DIVISION, 2019 (%)
FIGURE 64.PFIZER INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 65.PFIZER INC.: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 66.PFIZER INC.: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 67.SANOFI: NET SALES, 2017–2019 ($MILLION)
FIGURE 68.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 69.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 70.TEVA: NET SALES, 2017–2019 ($MILLION)
FIGURE 71.TEVA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 72.TORRENT: NET SALES, 2017–2019 ($MILLION)
FIGURE 73.TORRENT: REVENUE SHARE BY REGION, 2019 (%)

 
 

In recent times, with the COVID-19 outbreak, hydroxychloroquine demonstrated anti-viral activity against (SARS–CoV-2). Hydroxychloroquine, in combination with antibiotic azithromycin, holds the potential to treat COVID-19. In India, hydroxychloroquine is an over-the-counter drug, which can purchased without prescription, and is considered among the inexpensive medications. However, since the COVID-19 outbreak, purchasing the drug without prescription has been restricted. The growth of industry is majorly driven by such as rise in demand for the medication, globally. However, several side effects associated with the drug such as hypokalemia, drowsiness, headache, conduction disorders, rhythm, cardiovascular collapse restrain the growth of the hydroxychloroquine market. Intas Pharmaceuticals Ltd., an Indian company operating in Ahmedabad, announced its collaboration with World Health Organization-endorsed study in March 2020. Under the collaboration, the company is planning to supply around two million tablets. Zydus Cadila and IPCA Laboratories announced in April 2020 that they received an order of 10 crore tablets for the treatment of the condition from the Ministry of Health and Family Welfare, India.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total market size of global Hydroxychloroquine Market is $1,936.5 million in 2019.

A. Cadila Healthcare Ltd., Hikma Pharmaceuticals PLC, Ipca Laboratories Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Taj Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Zydus Cadila are the emerging players in the industry.

A. Malaria is the major area of development in the industry followed by rheumatoid arthritis.

A. Malaria and coronavirus are projected to increase demand for Hydroxychloroquine market.

A. Hydroxychloroquine market is driven by increased demand during the pandemic situation. The need for preventing the spread has driven the demand for Hydroxychloroquine further fostering the market growth.

A. The most influencing segment is hospital pharmacy and retail pharmacy in terms of distribution channel.

A. Asia-Pacific holds the maximum market share of the Hydroxychloroquine market.

A. Active pharmaceuticals ingredients are expected to drive the adoption of Hydroxychloroquine.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Hydroxychloroquine Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts